Abudayyeh Ala, Suo Liye, Lin Heather, Mamlouk Omar, Abdel-Wahab Noha, Tchakarov Amanda
Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX 77030, USA.
Department of Pathology and Laboratory Medicine, McGovern Medical School UTHealth, The University of Texas Health Science Center at Houston, 6431 Fannin Street, Houston, TX 77030, USA.
Cancers (Basel). 2022 Oct 27;14(21):5267. doi: 10.3390/cancers14215267.
Immune-related adverse events are a management challenge in patients receiving immune checkpoint inhibitors (ICIs). The most common renal immune-related adverse event, acute interstitial nephritis (AIN), is associated with patient morbidity and mortality. AIN, characterized by infiltration of renal tissue with immune cells, may be analogous to kidney transplant rejection. We evaluated clinical variables and pathologic findings to identify predictors of renal response and overall survival (OS) in patients with ICI-induced AIN.
DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: We reviewed the records and biopsy specimens of all 35 patients treated for ICI-induced AIN at our institution, between August 2007 and August 2020, who had biopsy specimens available. Two board-certified renal pathologists graded the severity of inflammation and chronicity using transplant rejection Banff criteria and performed immunohistochemistry analysis. Patients were categorized as renal responders if creatinine had any improvement or returned to baseline within 3 months of initiating treatment for AIN. Clinical and pathologic characteristics and OS were compared between responders and non-responders.
Patients with high levels of interstitial fibrosis were less likely to be responders than those with less fibrosis ( = 0.02). Inflammation, tubulitis, the number of eosinophils and neutrophils, and the clustering or presence of CD8+, CD4+, CD20+, or CD68+ cells were not associated with renal response. Responders had better OS than non-responders (12-month OS rate 77% compared with 27%, = 0.025). Responders who received concurrent ICIs had the best OS, and non-responders who did not receive concurrent ICIs had the worst OS (12-month OS rate 100% for renal response and concurrent ICIs, 72% for renal response and no concurrent ICIs, and 27% for no renal response and no concurrent ICIs; = 0.041).
This is the first analysis of ICI induced nephritis where a detailed pathological and clinical evaluation was performed to predict renal response. Low levels of interstitial fibrosis in kidney tissue are associated with renal response to treatment for ICI-induced AIN, and the renal response and use of concurrent ICIs are associated with better OS in these patients. Our findings highlight the importance of the early diagnosis and treatment of ICI-AIN, while continuing concurrent ICI therapy.
免疫相关不良事件是接受免疫检查点抑制剂(ICI)治疗的患者面临的管理挑战。最常见的肾脏免疫相关不良事件,即急性间质性肾炎(AIN),与患者的发病率和死亡率相关。AIN的特征是肾组织中有免疫细胞浸润,可能类似于肾移植排斥反应。我们评估了临床变量和病理结果,以确定ICI诱导的AIN患者肾脏反应和总生存期(OS)的预测因素。
设计、设置、参与者和测量方法:我们回顾了2007年8月至2020年8月期间在我们机构接受ICI诱导的AIN治疗且有活检标本的所有35例患者的记录和活检标本。两名获得董事会认证的肾脏病理学家使用移植排斥反应班夫标准对炎症和慢性程度进行分级,并进行免疫组织化学分析。如果肌酐在开始治疗AIN后3个月内有任何改善或恢复到基线水平,则将患者归类为肾脏反应者。比较反应者和无反应者的临床和病理特征以及OS。
间质纤维化程度高的患者比纤维化程度低的患者更不可能是反应者(P = 0.02)。炎症、肾小管炎、嗜酸性粒细胞和中性粒细胞的数量以及CD8 +、CD4 +、CD20 +或CD68 +细胞的聚集或存在与肾脏反应无关。反应者的OS比无反应者更好(12个月OS率分别为77%和27%,P = 0.025)。接受联合ICI治疗的反应者OS最佳,未接受联合ICI治疗的无反应者OS最差(肾脏反应且联合ICI治疗的12个月OS率为100%,肾脏反应且未联合ICI治疗的为72%,无肾脏反应且未联合ICI治疗的为27%;P = 0.041)。
这是首次对ICI诱导的肾炎进行分析,其中进行了详细的病理和临床评估以预测肾脏反应。肾组织中间质纤维化水平低与ICI诱导的AIN治疗的肾脏反应相关,并且肾脏反应和联合ICI的使用与这些患者更好的OS相关。我们的研究结果强调了在继续联合ICI治疗的同时,早期诊断和治疗ICI-AIN的重要性。